Chief Accounting Officer

Director

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Institution	Shares	Value	Change
BlackRock	10,287,156	$766M	DECREASED
State Street	4,435,932	$330M	DECREASED
Pictet Asset Management Holding	1,448,126	$107M	INCREASED
Principal Financial Group	1,024,423	$76M	DECREASED
Citigroup	864,101	$64M	INCREASED

Insider	Type	Shares	Value	Date
Maricel Apuli (Chief Accounting Officer)	SELL	2,000	$160K	2026-07-30
Jennifer E. Cook (Director)	EXERCISE	17,167	$288K	2026-07-09
Jennifer E. Cook (Director)	EXERCISE	112,422	$3M	2026-07-09
Jennifer E. Cook (Director)	EXERCISE	19,000	$161K	2026-07-09
Jennifer E. Cook (Director)	SELL	112,422	$10M	2026-07-09

Member	Type	Amount	Date
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-05-11
Gilbert Cisneros (Democrat)	PURCHASE	$1,001 - $15,000	2026-04-29

BridgeBio Pharma, Inc. Common Stock (BBIO) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades

Recent Congressional Trades